Electromedical Technologies, Inc. (EMED) intrinsic value & 10-year financials
Electromedical Technologies, Inc. (EMED) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 6 fiscal years revenue grew 12.9% a year to $1.3M, with an average return on invested capital of 460.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $37.7K
- Revenue (FY2023)
- $1.3M
- Revenue growth (6-yr CAGR)
- 12.9%
- ROIC (10-yr avg)
- 460.5%
- Free cash flow (FY2023)
- -$1.6M
EMED 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2023 | $1.3M | -$2.6M | $0.00 | -$1.6M | -153.1% | 114.3% |
| FY2022 | $1.1M | -$3.5M | -$0.03 | — | -139.5% | 298.9% |
| FY2021 | $907.4K | -$8.5M | -$0.24 | — | -418.8% | 1352.3% |
| FY2020 | $738.0K | -$3.9M | -$0.20 | — | -429.1% | 454.8% |
| FY2019 | $829.7K | -$1.7M | — | — | -201.1% | 82.2% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Electromedical Technologies, Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Electromedical Technologies, Inc has earned high returns on invested capital, averaging 43.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Electromedical Technologies, Inc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Electromedical Technologies, Inc is modeled at 12.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.